NCT02021097

Brief Summary

The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,008

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Feb 2012

Typical duration for phase_3

Geographic Reach
1 country

21 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

March 12, 2013

Completed
10 months until next milestone

First Posted

Study publicly available on registry

December 27, 2013

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
Last Updated

December 27, 2013

Status Verified

December 1, 2013

Enrollment Period

3 years

First QC Date

March 12, 2013

Last Update Submit

December 19, 2013

Conditions

Keywords

Levonorgestrel;Ethinyl Estradiol;Oral Contraceptive

Outcome Measures

Primary Outcomes (1)

  • The primary efficacy variable is the number of unintended pregnancies as measured by the Pearl Index (PI) during 13 cycles of treatment

    From fist dose to 13 treatment cycles (1 cycle=28 days)

Secondary Outcomes (2)

  • Menstrual Cycle Control

    From fist dose to 13 treatment cycles (1 cycle=28 days)

  • Weight changes

    From fist dose to 13 treatment cycles (1 cycle=28 days)

Study Arms (2)

LNG100 mcg/EE20 mcg

EXPERIMENTAL
Drug: Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg

LNG 150mcg/ EE 30mcg

ACTIVE COMPARATOR
Drug: Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg

Interventions

Tablet, orally, opd

LNG100 mcg/EE20 mcg

Tablet, orally, opd

LNG 150mcg/ EE 30mcg

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy women,aged 20-35 years who wish to use a contraceptive.
  • Women without reproductive system infection complications.
  • Willingness to not use other forms of hormonal treatment.
  • Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
  • Signed informed consent prior to entry into the trial.

You may not qualify if:

  • Any contraindication to the use of oral contraceptives.
  • Vascular, metabolic, hepatic, renal, oncologic and other diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Unknown Facility

Beijing, Beijing Municipality, 100039, China

NOT YET RECRUITING

Unknown Facility

Beijing, Beijing Municipality, 100730, China

NOT YET RECRUITING

Unknown Facility

Chongqing, Chongqing Municipality, 400010, China

RECRUITING

Unknown Facility

Chongqing, Chongqing Municipality, 400042, China

RECRUITING

Unknown Facility

Guangzhou, Guangdong, 510120, China

RECRUITING

Unknown Facility

Shantou, Guangdong, 515041, China

RECRUITING

Unknown Facility

Zhongshan, Guangdong, 528403, China

RECRUITING

Unknown Facility

Guiyang, Guizhou, 550000, China

RECRUITING

Unknown Facility

Guiyang, Guizhou, 550002, China

RECRUITING

Unknown Facility

Wuhan, Hubei, 430030, China

RECRUITING

Unknown Facility

Changde, Hunan, 415003, China

RECRUITING

Unknown Facility

Changsha, Hunan, 410013, China

RECRUITING

Unknown Facility

Nanjing, Jiangsu, 210009, China

RECRUITING

Unknown Facility

Nanjing, Jiangsu, 210036, China

RECRUITING

Unknown Facility

Yangzhou, Jiangsu, 225009, China

RECRUITING

Unknown Facility

Shanghai, Shanghai Municipality, 200021, China

RECRUITING

Unknown Facility

Taiyuan, Shanxi, 030013, China

RECRUITING

Unknown Facility

Xi’an, Shanxi, 710061, China

RECRUITING

Unknown Facility

Tianjin, Tianjin Municipality, 300211, China

RECRUITING

Unknown Facility

Ürümqi, Xinjiang, 830054, China

RECRUITING

Unknown Facility

Taizhou, Zhejiang, 317000, China

NOT YET RECRUITING

MeSH Terms

Interventions

LevonorgestrelEthinyl Estradiol

Intervention Hierarchy (Ancestors)

NorgestrelNorpregnenesNorpregnanesNorsteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsNorpregnatrienesEstrogenic Steroids, AlkylatedEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Chengliang Xiong, Dr

    Family Planning Research Institute of TJMC,HUST

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chengliang Xiong, Dr

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2013

First Posted

December 27, 2013

Study Start

February 1, 2012

Primary Completion

February 1, 2015

Study Completion

February 1, 2016

Last Updated

December 27, 2013

Record last verified: 2013-12

Locations